newsfilter
← Earnings
Earnings Releases·

Arvinas — Third Quarter 2026 Earnings Summary

Arvinas reported third-quarter 2026 financial results showing revenue of $0.5 million and a net loss of $53.9 million, with cash and marketable securities totaling $558.9 million as of September 30, 2026. The company initiated dosing in a Phase 1/2 trial for ARV-6723, its first immuno-oncology PROTAC targeting HPK1, and presented new biomarker data for ARV-102 in Parkinson's disease patients. Arvinas reaffirmed its commitment to share clinical data from ARV-393, ARV-027, and ARV-6723 during the fourth quarter of 2026 and throughout 2027. Additionally, the company plans to submit clinical trial applications for a Phase 1b trial of ARV-102 in progressive supranuclear palsy in the European Union and United Kingdom.

Company
ARVINAS INC
Sector
Healthcare
Industry
Biotechnology